Suzanne has over 20 years of cross-functional experience in both small and large innovative pharmaceutical organizations working with biologics, biosimilars, rare disease and medical devices.
Suzanne’s strength is her breadth and depth of knowledge garnered from her professional experience in market access, pricing, PMPRB, trade relations, hospital channel, corporate start-up and understanding of the Canadian landscape.
As a Director at Pangaea, Suzanne specializes in supporting start up organizations from corporate set-up including new or transitional drug products, product importation, product assessments and Canadian environmental reviews, as well as managing RFPs for 3PL and PSP services. At Pangaea, Suzanne also supports PMPRB filings; her pricing experience includes new molecules, product lifecycle analysis including price increases, price decrease mitigation plans and generic entry strategy.
Areas of expertise
- Corporate Strategy
- Business Strategy
- Trade Strategy
Recent articles by Suzanne Solman
Pangaea Express: PMPRB releases a statement, April 22, 2022
April 25, 2022
Pangaea Express: Supreme Court of Canada Dismisses Appeal in SOLIRIS case
March 28, 2022
Pangaea Express: Quebec Court of Appeal Case
February 25, 2022
Pangaea Express: Delay until July 1, 2022 for Patented Medicines Regulations
December 24, 2021
Pangaea Express: PMPRB Not Moving Forward July 15 with Proposed Changes
December 20, 2021